Biophan Issued New Patent for Solution to Enhance Image Quality of Magnetic Resonance Imaging -MRI- of Medical Devices.

ROCHESTER, N.Y. -- Biophan's Portfolio Now at 37 Issued U.S. Patents, 90 Additional Patents Pending, and 46 Pending and Issued International Patents

Biophan Technologies, Inc. (OTCBB:BIPH - News), a developer of next-generation medical technology, announced today that the U.S. Patent No. 6,902,290 has been granted to the Company. The patent teaches the placement of an electronic sensor within medical devices that can offset the image artifacts that interfere with the quality of MRI imaging.

The new patent supports Biophan's strategy of aggressive expansion of its intellectual property portfolio with proprietary solutions covering opportunities across several multi-billion-dollar segments of the healthcare and biomedical device marketplace.

The Company's intellectual property portfolio currently comprises 127 U.S. issued or pending patents and 46 international issued or pending patents, representing a commanding industry lead.

"This patent is part of our technology suite for making medical devices safe and compatible for operation with MRI imaging," said Michael Weiner, CEO of Biophan. "To the best of our knowledge, we hold directly or through exclusive licenses, the vast majority of the issued patents that address the safety and the image compatibility between MRI systems and implantable and interventional medical devices. This allows us to supply manufacturers with a toolkit of solutions to resolve the MRI-safety and image-quality problems inherent in many medical devices, both on the market and on the drawing boards."

Biophan's mission is to improve medical devices and offer them to strategic partners to impact their market share, producing revenue and profit for Biophan shareholders.

"This recently issued patent results from Biophan's conviction that solving the MRI safety problem alone is not sufficient," said Mr. Weiner. "The patent teaches modifying the circuitry of devices such as pacemakers to improve their compatibility with MRI. This is an extension to our technology suite, which includes an RF filter licensed from Johns Hopkins University, and anti-antenna geometry modifications that are placed in the wire lead connecting the implantable device to tissue for sensing or therapeutic function."

A growing body of published medical research is drawing attention to the need for improved safety and visualization of MRI imaging with these devices. Leading medical device makers, such as Medtronic Inc. (NYSE: MDT) and Guidant Corp. (NYSE: GDT), as well as the FDA, have all publicly expressed the need for technology solutions that will make the use of MRI both safe and effective for patients receiving these devices.

"Now that the critical need for making medical devices safe for use with MRI machines is gaining widespread recognition, Biophan is positioned to help device manufacturers design their devices to be safe and image compatible with MRI, and we can offer them a wide variety of solutions," said Mr. Weiner. "There is no longer any excuse for not making and certifying devices to be safe with MRI machines. It is important to bring an end to the many problems that have hampered recipients of these life enhancing medical devices from undergoing critical and beneficial MRI diagnostic procedures. We are pleased with the growing activity among device manufacturers interested in fixing the problem, and exploring the use of our patented solutions."

To view details of the newly issued patent, please visit http://www.biophan.com/newpatents/6901290.pdf.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 127 U.S. patents, licenses, or applications. This total includes 37 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 82 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE: BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.